SHELTON JENKINS: Open Payments
NPI 1689399198 · COEUR D ALENE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$710 in 20 payments from 10 companies in 2025. Trend: 2023 $167 · 2024 $257 · 2025 $710
Food & beverage: $598Education: $111
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $218 |
| Janssen Pharmaceuticals, Inc | 2 | $171 |
| Teva Pharmaceuticals USA, Inc. | 3 | $145 |
| Axsome Therapeutics, Inc. | 2 | $60 |
| ABBVIE INC. | 1 | $26 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Neurocrine BioSciences, Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
Products named: CAPLYTA, INVEGA SUSTENNA, REXULTI, UZEDY, Auvelity, Sunosi, VRAYLAR, FANAPT.
Industry payments across ID — which companies pay providers there.
